Komori
Bml (4694) · PolicyAdvanced

Review of the Rationale for Strategic Shareholdings and Decisions on Sales

First written in FY2019. 3 of 5 entries say "Advanced", first in FY2020. Latest entry: FY2026.

5entries
8years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2019AdvancedFY2020 – FY2022RestatedFY20252019: 120192020: 120202021: 020212022: 120222023: 020232024: 020242025: 120252026: 12026
Same theme, other companies
Verification of the Rationale for Strategic ShareholdingsA theme 1515 companies write about · 1 as a headwind · 790 as a tailwind
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 200 companies compared. The sentences above are computed from all 200.Comparing 200 of the theme's 1520 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「Following consideration by the Board of Directors and other bodies of the significance of holding the shares, the Company sold them.」

    The Company sold 3 cross-held equity investments: Resona Holdings, Inc., Dai-ichi Life Holdings, Inc. and Sumitomo Mitsui Financial Group, Inc.
  2. FY2025RestatedAnnual report

    「For each individual cross-held equity investment, the Company conducts an annual comprehensive review of the investment's medium- to long-term economic rationale and future outlook, the associated risks and returns, and the significance of holding it in its business strategy, including business relationships and business alliances, and determines whether to continue holding it.」

    The Company continues its policy of reviewing cross-held equity investments annually and determining whether to continue holding or sell them. During the fiscal year, there were no investments in which the number of shares changed.
  3. FY2022AdvancedAnnual report

    「If holding an investment is deemed unjustified, the Company will proceed with its sale while obtaining the understanding of the relevant investee. Even where holding an investment is deemed justified, the Company may sell it after taking into account market conditions and its management and financial strategies.」

    The Company continued its policy of reviewing cross-held equity investments annually, and during the fiscal year sold 2 investments other than unlisted equity investments.
  4. FY2020AdvancedAnnual report

    「Following consideration by the Board of Directors and other bodies of the significance of holding the shares, the Company sold them.」

    Following consideration by the Board of Directors and other bodies of the significance of holding cross-held equity investments, the Company sold 3 unlisted and 6 listed equity investments.
  5. FY2019First statedAnnual report

    「For each individual cross-held equity investment, the Company conducts an annual comprehensive review of the investment's medium- to long-term economic rationale and future outlook, the associated risks and returns, and the significance of holding it in its business strategy, including business relationships and business alliances, and determines whether to continue holding it.」

    It has disclosed for the first time a policy of limiting cross-held equity investments and annually reviewing their economic rationale, risks, returns and significance to business strategy to determine whether to continue holding or sell them.
Moved together

"Transition to Restricted Stock Compensation" moved the same way as this thread, in the same document, in 3 of its 5 moves.

333322★123456
  1. ★This thread
  2. 1Transition to Restricted Stock Compensation3×
  3. 2Maintaining stable dividends and increasing dividend levels3×
  4. 3Automation of testing operations, regional laboratory expansion and faster turnaround3×
  5. 4Improving the work environment, treatment of non-regular employees, and advancement of women3×
  6. 5Strengthening Competitiveness in the Clinical Testing Business2×
  7. 6Growth of the electronic medical records and medical information systems businesses2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Bml's next results are scheduled for 2026-11-11. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.